Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 89.4%

Neg 89.4% Neu 0% Pos 0%

Craig-Hallum analyst Albert Lowe downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold and lowers the price target from $10 to $2.